Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunoglobulin prophylaxis for hepatitis A.

P L Winokur1, J T Stapleton

  • 1Department of Internal Medicine, University of Iowa, Iowa City 52242.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|February 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Navigating false positive HIV test results: a case report.

ASM case reports·2025
Same author

Human pegivirus viremia in HCV/HIV co-infected patients: Direct acting antivirals exert anti-pegivirus effects.

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology·2023
Same author

Infection of Glia by Human Pegivirus Suppresses Peroxisomal and Antiviral Signaling Pathways.

Journal of virology·2021
Same author

Transmission of GB virus type C via transfusion in a cohort of HIV-infected patients.

The Journal of infectious diseases·2012
Same author

GB virus C infection among young, HIV-negative injection drug users with and without hepatitis C virus infection.

Journal of viral hepatitis·2010
Same author

Effect of antiretroviral therapy and hepatitis c co-infection on changes in lipid levels in HIV-Infected patients 48 weeks after initiation of therapy.

HIV clinical trials·2007

Immunoglobulin (IG) effectively prevents hepatitis A, but its protection is temporary. New hepatitis A virus (HAV) vaccines are emerging, and studying antibody responses to IG can assess their effectiveness.

Area of Science:

  • Hepatology
  • Immunology
  • Vaccinology

Background:

  • Hepatitis A Virus (HAV) infection poses a significant public health concern.
  • Immunoglobulin (IG) has demonstrated 80%-90% efficacy in preventing Hepatitis A when administered prophylactically.
  • Short-lived protection necessitates early diagnosis and prompt IG administration for contacts.

Purpose of the Study:

  • To review the role of immunoglobulin (IG) in preventing Hepatitis A.
  • To emphasize the relationship between antibody response after IG administration and the efficacy of Hepatitis A virus (HAV) vaccines.
  • To explore the use of antibody evaluation in IG and recipients for assessing HAV vaccine immunogenicity.

Main Methods:

  • Review of studies on immunoglobulin efficacy over the past 45 years.

Related Experiment Videos

  • Analysis of antibody responses to Hepatitis A virus (HAV) in immunoglobulin preparations.
  • Evaluation of antibody levels in individuals receiving immunoglobulin post-exposure.

    • Main Results:

    • Immunoglobulin (IG) provides substantial, albeit temporary, protection against Hepatitis A.
    • Early diagnosis and timely IG administration are critical for effective prevention.
    • Antibody levels in IG and recipients serve as a metric for assessing vaccine immunogenicity.

    Conclusions:

    • Immunoglobulin (IG) remains a valuable tool for Hepatitis A prevention, particularly in post-exposure prophylaxis.
    • The development of inactivated and attenuated Hepatitis A virus (HAV) vaccines is imminent.
    • Assessing antibody responses is crucial for validating the immunogenicity and efficacy of new HAV vaccines.